Cancer/testis antigen HCA587-derived long peptide vaccine generates potent immunologic responses and antitumor effects in mouse model

Oncol Res. 2013;21(4):193-200. doi: 10.3727/096504014X13887748696789.

Abstract

The cancer/testis antigen HCA587 (also known as MAGE-C2), one of the most immunogenic tumor antigens, is overexpressed in a wide spectrum of malignant tumors and can serve as a target for immunotherapy. In this study, we synthesized 14 overlapping (25-35 amino acids) long peptides representing the sequence of the most immunogenic part of the HCA587 protein and evaluated the antigen-specific immune responses and antitumor effects generated by immunization with the synthetic long peptide (SLP) vaccine in a mouse model. HCA587 SLPs in combination with adjuvants CFA and CpG ODN induced potent T-cell responses, which were dominated by type 1 cytokine IFN-γ-producing CD4(+) T cells as measured by ELISPOT and intracellular cytokine staining assay. Moreover, HCA587 SLP vaccination conferred protection against challenge with HCA587-expressing B16 melanoma in a therapeutic setting. Our findings may provide a scientific basis for the use of HCA587-derived long overlapping peptide vaccine for the treatment of patients with cancer in future clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology*
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / pharmacology*
  • Cell Growth Processes / drug effects
  • Cell Growth Processes / immunology
  • Disease Models, Animal
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Proteins / immunology*
  • Peptide Fragments / immunology
  • Peptide Fragments / pharmacology
  • Recombinant Proteins / immunology
  • Recombinant Proteins / pharmacology

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines
  • MAGEC2 protein, human
  • Neoplasm Proteins
  • Peptide Fragments
  • Recombinant Proteins